Pyxis Oncology Inc Asset Resilience Ratio
Pyxis Oncology Inc asset resilience ratio. Pyxis Oncology Inc (PYXS) has an Asset Resilience Ratio of 63.76% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Pyxis Oncology Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pyxis Oncology Inc (2022–2024)
Asset resilience ratio of Pyxis Oncology Inc from 2022 to 2024. This chart shows how Pyxis Oncology Inc's Asset Resilience Ratio has changed over time. Read PYXS total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pyxis Oncology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Pyxis Oncology Inc (PYXS) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $67.34 Million | 63.76% |
| Total Liquid Assets | $67.34 Million | 63.76% |
Asset Resilience Insights
- Very High Liquidity: Pyxis Oncology Inc maintains exceptional liquid asset reserves at 63.76% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pyxis Oncology Inc Industry Peers by Asset Resilience Ratio
Compare Pyxis Oncology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Pyxis Oncology Inc Asset Resilience Ratio by Year (2022–2024)
Pyxis Oncology Inc asset resilience ratio by year from 2022 to 2024. The table below shows the annual Asset Resilience Ratio data for Pyxis Oncology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 68.37% | $107.46 Million | $157.18 Million | +5.26pp |
| 2023-12-31 | 63.11% | $109.63 Million | $173.73 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $211.38 Million | -- |
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candida… Read more